Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing
With several recent FDA approvals and a strong drug pipeline, the gene therapy market is coming of age and providing new hope for patients. As demand for these new therapies increases, a robust and scalable manufacturing process is critical. In this webinar, we will present an end user case study which illustrates the challenges and solutions to scale both the upstream and downstream process steps required to manufacture adenoviruses.
Participants will learn how to:
• Accelerate time to market for adenovirus manufacturing
• Design the process for scalability
• Reduce downstream processing time from 3 - 4 days to 1 day
Speakers
Clive Glover, PhD
Rachel Legmann, PhD
Senior Manager, Process Development Services
Pall Biotech
Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing
Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing
Biotech | Pall Corporation webinar series
Why the introduction of X-ray sterilization technology is a critical change for single-use industry, and how gamma and X-ray irradiation compare
The market demand for gamma irradiation, the current primary method for the sterilization in SUT, will soon significantly exceed supply, creating an urgent need for alternatives.
Join Christelle Marcoux from GSK Vaccines (BioPhorum workstream member on alternatives to gamma sterilization) and James Hathcock, PhD of Pall Corporation (Bio-Process Systems Alliance X-Ray Committee Co-Chair) as they discuss the introduction of X-ray sterilization technology.
You will learn more about:
- Why this is a critical change for industry and the responsibilities of each stakeholder
- Key questions to address for biomanufacturers
- How gamma and X-ray irradiation compare
- What testing has been completed and key milestones for readiness for industry
- An example of how to qualify a SUS sterilized with X-ray irradiation